Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.35 |
| ▸ | BCL2 | P10415 | 2/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | KCNQ3 | O43525 | 3/20 | 0.34 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23895822 | 1.00 | PDE10A (0.37) | PDE10AMCL1BCL2BCL2L1KCNQ3 | |
| SCHEMBL28974972 | 1.00 | PDE10A (0.37) | PDE10AMCL1BCL2BCL2L1KCNQ3 | |
| SCHEMBL25558990 | 0.91 | PDE10A (0.38) | PDE10AMCL1BCL2BCL2L1KCNQ3 | |
| SCHEMBL23896035 | 0.91 | PDE10A (0.38) | PDE10AMCL1BCL2BCL2L1KCNQ3 | |
| SCHEMBL23896036 | 0.91 | PDE10A (0.38) | PDE10AMCL1BCL2BCL2L1KCNQ3 | |
| SCHEMBL23895820 | 0.89 | TRPV3 (0.35) | PDE10AMCL1BCL2L1KCNQ3KCNQ2 | |
| SCHEMBL25544155 | 0.89 | TRPV3 (0.35) | PDE10AMCL1BCL2L1KCNQ3KCNQ2 | |
| SCHEMBL23896419 | 0.89 | CTSA (0.35) | KCNQ3KCNQ2TOP1 | |
| SCHEMBL23896415 | 0.89 | CTSA (0.35) | KCNQ3KCNQ2TOP1 | |
| SCHEMBL23896209 | 0.88 | SCN9A (0.39) | PDE10AMCL1BCL2BCL2L1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | PDE10A 3701/4885MCL1 2407/4885BCL2 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.